Nirsevimab - MedImmune

Drug Profile

Nirsevimab - MedImmune

Alternative Names: Anti-RSV mAb D25; Anti-RSV MAb-YTE; MEDI-8897; Respiratory syncytial virus monoclonal antibody D25; SP 0232

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AIMM Therapeutics
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Respiratory syncytial virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in USA (IM)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in USA (IV)
  • 08 Oct 2017 Safety and pharmacokinetics data from a phase-I/II trial in Respiratory syncytial virus infections presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top